Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4
EY Chew, JP SanGiovanni, FL Ferris… - JAMA …, 2013 - jamanetwork.com
Importance Age-related cataract is a leading cause of visual impairment in the United States.
The prevalence of age-related cataract is increasing, with an estimated 30.1 million
Americans likely to be affected by 2020. Objective To determine whether daily oral
supplementation with lutein/zeaxanthin affects the risk for cataract surgery. Design, Setting,
and Patients The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-
masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression …
The prevalence of age-related cataract is increasing, with an estimated 30.1 million
Americans likely to be affected by 2020. Objective To determine whether daily oral
supplementation with lutein/zeaxanthin affects the risk for cataract surgery. Design, Setting,
and Patients The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-
masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression …